The stomach cancer market size is projected to grow from US$ 3,575.04 million in 2022 to US$ 10,751.42 million by 2030; it is estimated to record a CAGR of 14.8% during 2022-2030.

Key factors driving the market growth include the growing incidence of stomach cancer, advancements in treatment, including chemotherapy, surgery, and targeted therapies, and ongoing research and development efforts to improve patient outcomes. With the increasing emphasis on early diagnosis and personalized treatment approaches, the stomach cancer treatment market is expected to continue to expand in the future.

Stomach cancer, also known as gastric cancer, is caused by the abnormal and out-of-control growth of malignant cells in the stomach. Risk factors that lead to the risk of stomach cancer include age and food. Indigestion, stomach discomfort, loss of appetite, heartburn, and weight loss are all symptoms of stomach cancer. Different approaches are employed in treating stomach cancers, such as chemotherapy, radiation therapy, and immunotherapy.

Rising Burden of Stomach Cancer to Drive Stomach Cancer Market Growth

Stomach cancer, also known as gastric cancer, is regarded as one of the major health challenges worldwide. The stomach is lined with a mucous membrane composed of cells and glands. Before a true cancer develops, pre-cancerous changes occur in the inner lining of the stomach. The cells are prone to inflammation, leading to peptic ulcers, which could potentially become gastric cancer. The early signs of gastric cancer include nausea, indigestion, loss of appetite, heartburn, and other symptoms. When stomach cancer is severe, signs such as yellowish eyes or skin, stomach pain, swelling in the stomach, blood in stool, vomiting, constipation, and weight loss can be detected. Regardless of declining incidence and mortality during the last decades, stomach cancer is considered one of the major health issues worldwide.

Gastric cancer is the 5th most common cancer worldwide, and it was 4th leading cause of cancer mortality in both genders combined in 2020. As per Global Cancer Statistics 2020: GLOBOCAN estimates, in 2020, ~1.1 million gastric cancer cases (720,000 males and 370,000 females) were diagnosed worldwide, accounting for 5.6% of all cancer cases. Stomach cancer caused ~800,000 deaths (representing 7.7% of all cancer-related deaths) in 2020. Eastern Asian and Eastern European regions showed the highest incidence rates in both males and females; about two-thirds of all cases occurred in men.

Thus, the increasing number of cases of stomach cancer fuels the need for different types of treatment among people, driving the growth of the stomach cancer market.

Industry Developments and Future Opportunities:

Numerous initiatives taken by key players operating in the global stomach cancer market are listed below:

In January 2021, AstraZeneca and Daiichi Sankyo Company received the approval of Enhertu from the US FDA for treating adult patients with advanced or metastatic HER2-positive gastric adenocarcinoma

Moreover, the increasing company activities in conducting clinical trials for developing effective drugs for patients with gastric cancer and increasing product launches and approvals are estimated to fuel the market growth in the region. In April 2021, the Food and Drug Administration (FDA) approved Bristol Myers Squibb's Opdivo, in combination with fluoropyrimidine and platinum-containing chemotherapy, for treating patients with advanced or metastatic gastric cancer and esophageal adenocarcinoma. Thus, such factors are likely to support the market growth in the region during the forecast period.

SEGMENTAL OVERVIEW

The stomach cancer market, by type, is categorized into adenocarcinomas, gastrointestinal stromal tumors, neuroendocrine tumors, lymphoma, and others. The adenocarcinomas segment held a significant market share in 2022 and is expected to register the highest CAGR in the stomach cancer market from 2022 to 2030.

Based on treatment, the stomach cancer market is categorized into targeted and immunotherapy drugs, chemotherapy and combination drugs, and others. 2022 the chemotherapy and combination drugs segment held a significant market share. The targeted and immunotherapy drugs segment is expected to register the highest CAGR in the stomach cancer market from 2022 to 2030.

Based on the route of administration, the stomach cancer market is segmented into oral, parenteral, and others. In 2022, the oral segment held a significant share of the market, and it is anticipated to record the fastest CAGR during 2022-2030.

Based on the distribution channel, the stomach cancer market is categorized into hospital, retail, and online pharmacies. The hospital pharmacies segment held a significant share of the market in 2022 and is expected to register the highest CAGR during 2022-2030.